Compare HWKN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | XNCR |
|---|---|---|
| Founded | 1938 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 1995 | 2013 |
| Metric | HWKN | XNCR |
|---|---|---|
| Price | $124.58 | $27.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $200.00 | $22.33 |
| AVG Volume (30 Days) | 108.5K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $1,083,696,000.00 | $125,576,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.30 | $4.80 |
| P/E Ratio | $89.09 | ★ N/A |
| Revenue Growth | 11.21 | ★ 13.65 |
| 52 Week Low | $116.05 | $7.91 |
| 52 Week High | $186.15 | $30.61 |
| Indicator | HWKN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 65.43 |
| Support Level | $120.87 | $11.20 |
| Resistance Level | $156.25 | $30.61 |
| Average True Range (ATR) | 3.99 | 1.54 |
| MACD | 0.40 | -0.09 |
| Stochastic Oscillator | 43.87 | 66.83 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The Industrial Solutions segment, provides industrial chemicals, products and services to industries such as industrial manufacturing, chemical processing, electronics, energy, plating, and surface finishing. The water treatment segment, which generates the majority of revenue sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. Food and Health Sciences segment specializes in processing and formulation solutions as well as ingredient distribution to manufacturers in the nutrition, food, pharmaceutical, and agricultural markets.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.